Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of
intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric
cancer with gross peritoneal carcinomatosis (GC-PC).